Compare
First Choice Healthcare Solutions, Inc. vs BioNexus Gene Lab Corp vs Aclarion, Inc. vs YD Bio Ltd
| Latest fiscal year | First Choice Healthcare Solutions, Inc. FCHS | BioNexus Gene Lab Corp BGLC | Aclarion, Inc. ACON | YD Bio Ltd YDES |
|---|---|---|---|---|
| Year ended | 2025-12-31 | 2025-12-31 | 2025-12-31 | 2025-12-31 |
| Revenue | n/a | $7.42M | $75.7K | $596.8K |
| Revenue growth (YoY) | n/a | -21.9% | +65.6% | +16.9% |
| Gross margin | n/a | 14.6% | 9.0% | 28.1% |
| Operating margin | n/a | -39.9% | n/m | -883.3% |
| Net margin | n/a | -40.2% | n/m | n/m |
| Net income | -$6.96M | -$2.98M | -$7.23M | -$8.31M |
| EPS (Diluted) | -$0.21 | n/a | -$13.61 | -$0.12 |
| Operating cash flow | -$549.0K | -$1.84M | -$7.16M | -$6.60M |
| Free cash flow | n/a | -$1.88M | -$7.19M | -$8.04M |
| Cash & equivalents | $5.9K | $2.49M | $12.02M | $6.01M |
| Total assets | $4.05M | $9.25M | $13.67M | $13.78M |
| Total liabilities | $43.58M | $637.9K | $837.3K | $16.64M |
| Shareholders' equity | -$39.53M | $8.61M | $12.84M | -$2.86M |
| Return on year-end equity | n/a | -34.6% | -56.4% | n/a |
| Shares outstanding | 32.96M | 2.42M | 854.4K | 70.79M |
Revenue, most recent five fiscal years
| Fiscal year | First Choice Healthcare Solutions, Inc. | BioNexus Gene Lab Corp | Aclarion, Inc. | YD Bio Ltd |
|---|---|---|---|---|
| Latest | $1.05M Ended 2013-12-31 | $7.42M Ended 2025-12-31 | $75.7K Ended 2025-12-31 | $596.8K Ended 2025-12-31 |
| 1 year earlier | $1.16M Ended 2012-12-31 | $9.51M Ended 2024-12-31 | $45.7K Ended 2024-12-31 | $510.4K Ended 2024-12-31 |
| 2 years earlier | $1.30M Ended 2011-12-31 | $9.77M Ended 2023-12-31 | $75.4K Ended 2023-12-31 | $350.1K Ended 2023-12-31 |
| 3 years earlier | $1.26M Ended 2010-12-31 | $10.93M Ended 2022-12-31 | $60.4K Ended 2022-12-31 | n/a |
| 4 years earlier | n/a | $13.36M Ended 2021-12-31 | $60.3K Ended 2021-12-31 | n/a |